ArQule, Inc. (NASDAQ:ARQL) Stock Hits 17-Year Highs Amid Positive News

ArQule, Inc. (NASDAQ:ARQL)

Biotech company ArQule, Inc. (NASDAQ:ARQL), which is involved in...

Stay Ahead of the
Stock Market Game!
Subscribe to Small Cap
Exclusive for more


Cpmg Inc. Picked Up Reata Pharmaceuticals Inc. (NASD...
Infinity Pharmaceuticals (NASDAQ:INFI) Stock Bounces...
Relief Therapeutics Holding AG (RLFTF) Stock Makes a...

Biotech company ArQule, Inc. (NASDAQ:ARQL), which is involved in manufacturing precision cancer medicines, has been one of the most significant gainers in the market over the past two weeks. As of now, ArQule, Inc. stock has gained as much as 75% over the past two weeks.

Clinical Trial Of ARQ 531

It all started back on 14 June, when ArQule released the interim data from Phase 1 of the clinical trial for its medicine ARQ 531. The medicine in question is meant for the treatment of blood cancers and the results were encouraging. The data with relation to the proof of concept metrics showed that the medicine has the potential to be used to treat a whole range of blood cancers.

The data clearly indicated that the ARQ 531 product has the merits to go on to become an effective treatment for blood cancers and on that note, the stock started climbing. It rose by as much as 44.7% that day. However, that was not the end of the ArQule rally and a few days later the stock started climbing again after interim data was released for another medicine.

[thrive_leads id=’8276′]

Clinical Trial Of ARQ 092

On 17 June, ArQule revealed that the interim data from the clinical test of ARQ 092 was largely positive. The medicine in question is meant for the treatment of rare overgrowth diseases. On the same day that this news broke, the stock soared by as much as 21% to make ArQule one of the biggest gainers in the market.

According to experts, the impressive growth in the ArQule stock over the past two weeks is down to the fact that investors are now able to witness a lot of promise in the company’s pipeline of medicines. When a company has more than one promising product with encouraging data, then it is not a surprise to witness its stock having a good time.

ARQL stock is one of the biggest biotech stock gainers this year with a gain of over 280% since the beginning of this year. Moreover, the stock made a new 17-year high of $11.11 earlier in the session.

Stay in the lopp :

IDGlobal Corp (OTCMKTS:IDGC) Stock Gets High ...

IDGlobal Corp (OTCMKTS:IDGC) was in focus among investors yesterday after the company made a key announcement and the stock rallied accordingly as well.

Net Savings Link Inc (NSAV) Stock Makes a Bul...

Over the course of the past year or so, many companies which are involved in the cryptocurrency sector have come into considerable focus

Columbia Wanger Asset Management is Buying Ce...
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Celldex Therapeutics Inc. (NASDAQ:CLDX) reported that Columbia Wanger Asset Management

related post

Skip to content